ADCs for HER2 + MBC
- Review clinical data in HER2 + MBC from ESMO 2021
- Discuss optimal therapy selection based on individual patient characteristics in the HER2-positive metastatic breast cancer setting
- Describe potential adverse events associated with current treatment options for HER2-positive metastatic breast cancer
Stephen K. Chia, MD, FRCP
Shanu Modi, MD
This program has been made possible through unrestricted support from AstraZeneca.